Literature DB >> 19967500

Anticholinergic treatment in airways diseases.

Robert A Flynn1, Deirdre A Glynn, Marcus P Kennedy.   

Abstract

The prevalence of chronic airways diseases such as chronic obstructive pulmonary disease and asthma is increasing. They lead to symptoms such as a cough and shortness of breath, partially through bronchoconstriction. Inhaled anticholinergics are one of a number of treatments designed to treat bronchoconstriction in airways disease. Both short-acting and long-acting agents are now available and this review highlights their efficacy and adverse event profile in chronic airways diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19967500     DOI: 10.1007/s12325-009-0074-x

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  3 in total

1.  Central Anticholinergic Adverse Effects and Their Measurement.

Authors:  Pasi Lampela; Teemu Paajanen; Sirpa Hartikainen; Risto Huupponen
Journal:  Drugs Aging       Date:  2015-12       Impact factor: 3.923

Review 2.  Anticholinergics/antimuscarinic drugs in asthma.

Authors:  Xavier Soler; Joe Ramsdell
Journal:  Curr Allergy Asthma Rep       Date:  2014-12       Impact factor: 4.806

3.  Anticholinergic drug use, serum anticholinergic activity, and adverse drug events among older people: a population-based study.

Authors:  Pasi Lampela; Piia Lavikainen; J Arturo Garcia-Horsman; J Simon Bell; Risto Huupponen; Sirpa Hartikainen
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.